CPIX (Cumberland Pharmaceuticals) Institutional Ownership: 21.18% (As of Jul. 02, 2026)


CPIX Cumberland Pharmaceuticals Inc CPIX
36 GF Score
Price $6.43
GF Value $2.16
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Cumberland Pharmaceuticals Institutional Ownership?

Cumberland Pharmaceuticals CPIX -10.66% 36 Institutional Ownership is 21.18% as of Jul. 02, 2026. GuruFocus rates CPIX with a GF Score™ of 36/100 and a GF Value™ of $2.16 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cumberland Pharmaceuticals's institutional ownership is 21.18%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cumberland Pharmaceuticals's Insider Ownership is 51.20%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cumberland Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 58.50%.

Cumberland Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Cumberland Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cumberland Pharmaceuticals Institutional Ownership Chart

Cumberland Pharmaceuticals Historical Data

The historical data trend for Cumberland Pharmaceuticals can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 8.07 8.09 8.09 7.63 7.61 7.65 7.13 7.28 7.18 7.08
CPIX
36GF Score
Cumberland Pharmaceuticals Inc CPIX
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cumberland Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 21.18% mean?
Cumberland Pharmaceuticals (CPIX) has a Institutional Ownership of 21.18% as of Jul. 02, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cumberland Pharmaceuticals and its competitors.
Is Cumberland Pharmaceuticals' Institutional Ownership too high?
Cumberland Pharmaceuticals' current Institutional Ownership is 21.18%. Overall, Cumberland Pharmaceuticals has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cumberland Pharmaceuticals' Institutional Ownership compare to INCR and CTOR?
Cumberland Pharmaceuticals' Institutional Ownership of 21.18% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cumberland Pharmaceuticals and its competitors. Cumberland Pharmaceuticals's current Institutional Ownership is 21.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cumberland Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Cumberland Pharmaceuticals (CPIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.16, compared to a current price of $6.43 — trading 197.7% above its estimated fair value. The current Institutional Ownership is 21.18%. Cumberland Pharmaceuticals' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Cumberland Pharmaceuticals (CPIX), the current Institutional Ownership is 21.18% as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cumberland Pharmaceuticals (CPIX) Overvalued in 2026?

Based on GuruFocus' analysis, Cumberland Pharmaceuticals stock appears to be overvalued. The current stock price of $6.43 is trading 197.7% above its estimated GF Value™ of $2.16. GuruFocus considers Cumberland Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CPIX:

  • Institutional Ownership: 21.18%
  • GF Value™: $2.16 vs. price of $6.43 (197.7% above fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the CPIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cumberland Pharmaceuticals Business Description

Address 1600 West End Avenue, Suite 1300, Nashville, TN, USA, 37203
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
36GF Score

Get the complete analysis for CPIX

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.43
Price
$2.16
GF Value